Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy. Read more about Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.
A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI). Read more about A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).
Reliability of real-world data for diagnosis of metastatic prostate cancer. Read more about Reliability of real-world data for diagnosis of metastatic prostate cancer.
Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP). Read more about Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
Disparities in receipt of financial assistance for patients prescribed oral anti-cancer medications at an integrated specialty pharmacy. Read more about Disparities in receipt of financial assistance for patients prescribed oral anti-cancer medications at an integrated specialty pharmacy.
Between and within drug variation in copayments for common oral anti-cancer medications at an academic medical center. Read more about Between and within drug variation in copayments for common oral anti-cancer medications at an academic medical center.
Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group. Read more about Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group.
Convection-delivered adenoviral gene therapy reprograms the immunosuppressive glioblastoma microenvironment. Read more about Convection-delivered adenoviral gene therapy reprograms the immunosuppressive glioblastoma microenvironment.
A targeted gene expression biomarker and association with meningioma outcomes and radiotherapy. Read more about A targeted gene expression biomarker and association with meningioma outcomes and radiotherapy.
Trends in assessing and offering tobacco treatment to support persons as part of cancer care. Read more about Trends in assessing and offering tobacco treatment to support persons as part of cancer care.
